Tapestri Solution for Solid Tumor Research offers improved CNV analysis capability, in addition to breast cancer and glioblastoma research panels
SOUTH SAN FRANCISCO, Calif., March 29, 2022 – Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today launched the Tapestri Solution for Solid Tumor Research. This new end-to-end single-cell DNA sequencing workflow on the Tapestri Platform includes nuclei isolation prep protocol, pre-designed research panels for breast cancer and glioblastoma multiforme, and an improved single-cell copy number variation (CNV) bioinformatic analysis tool. Through the new capabilities, Mission Bio now offers solid tumor coverage in addition to hematologic cancers, where researchers routinely utilize Tapestri to probe tumor heterogeneity and leverage it for new understandings of clonal diversity and architecture underlying disease progression, biomarkers, and clinical practice.
Recent high-profile research studies using custom Tapestri assays for breast cancer, non-small cell lung cancer, colorectal cancer, and melanoma have shown the utility of high-resolution tools to better assess solid tumor heterogeneity and clonal evolution, which contribute to the onset, progression, and relapse of the disease. Bulk next-generation sequencing methods are unable to provide the cell-by-cell mutational data necessary to identify biological drivers of disease – they are limited to portraying only population-level average metrics, and lack clear data on clonal diversity.
Tapestri accurately measures DNA alterations at the individual cell level in thousands of cells at a time, co-detecting single nucleotide variations (SNVs), indels, and CNVs, definitively identifying variant zygosity and mutational co-occurrence, and detecting rare cell populations. Solid tumor researchers can now leverage a complete workflow optimized for the Tapestri Platform including:
All together, this total workflow solution can help the field both deepen our understanding of disease progression and develop more precise therapies.
The commercial launch of Mission Bio’s Tapestri Solution for Solid Tumor Research highlights the company’s continued dedication to enabling cancer research at a higher resolution more broadly with single-cell DNA sequencing. To drive best practices for solid tumor single-cell DNA profiling, Mission Bio recently announced its first Center of Excellence at Memorial Sloan Kettering Cancer Center (MSKCC).
“The impressive results already seen from our early work with solid tumor researchers helped guide the development of these new workflows, and underscored our commitment to providing unique and indispensable tools for solid tumor researchers. Just as Tapestri has been an invaluable tool for hematologic malignancy researchers, we’re confident that our research panel pair, new prep protocol, and improved bioinformatics analysis capabilities will demonstrate the platform’s value in solid tumors,” said Yan Zhang, PhD, CEO of Mission Bio.
For more on Mission Bio and the Tapestri platform, please visit missionbio.com.
About Mission Bio
Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies. Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.
The company’s Tapestri platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our expectations regarding the transaction described above, including anticipated benefits, anticipated payments, future business and market opportunities, and anticipated growth resulting from the transaction; the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; our position as a leader in the development of genetic medicines; and the sufficiency of our cash and cash equivalents to fund our operations; These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we may not realize the anticipated benefits of the collaboration with Oxford Biomedica; the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and our other filings with the Securities and Exchange Commission (“the SEC”) could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Consort Partners for Mission Bio